I am an Associate Professor of Medicine (Neurology) at McMaster University in Hamilton, Canada where I hold the Marta and Owen Boris Chair in Stroke Research and Care and previously served as Director of the Stroke Fellowship Program, and a Scientist at the affiliated Population Health Research Institute (PHRI). I obtained my M.D. from McMaster University in 2007 and completed my Neurology residency at the University of British Columbia in 2012, followed by clinical and research fellowship training in Vascular Neurology at the Boston University School of Medicine/Framingham Heart Study (2012-13) and Massachusetts General Hospital, Harvard Medical School (2013-14).
My primary research focus is the characterization of hemorrhage-prone cerebral small vessel disease (CSVD) and the optimization of clinical care in this patient population. The risk-benefit analysis of antithrombotic, lipid lowering and fibrinolytic therapy in patients who have previously suffered ICH, or have underlying occult hemorrhage-prone CSVD, is of particular interest. Towards these aims, I’m the founding Director of the Hemorrhagic Stroke Research Program at the PHRI and founding Chair of the Canadian Hemorrhagic Stroke trIals IniatiVE (CoHESIVE; www2.phri.ca/cohesive/), which is a Canada-centric international collaborative network of 50+ investigators devoted to the development and efficient execution of ICH trials, and to bettering the lives of ICH survivors. I am the lead PI of the ENRICH-AF trial (NCT03950076), which is an international multicenter PROBE trial conducted at over 300 centers across 23 countries that is investigating optimal antithrombotic therapy in patients with high-risk atrial fibrillation and previous intracranial hemorrhage. I additionally serve on the Steering and/or Executive Committees of several public and industry funded international randomized trials targeting secondary stroke prevention and the reversal of anticoagulant-related hemorrhage.
I have published over 90 peer-reviewed manuscripts in leading scientific journals (H-index: 27), and been granted over $54 million CAD in research funding since 2015 (~$29 million CAD as [Co-]PI). My work has been recognized by the most prestigious early career awards in stroke granted by the American Heart/Stroke Association (2015 Mordecai Y.T. Globus and 2019 Robert G. Siekert New Investigator Awards in Stroke), Heart and Stroke Foundation of Canada (2019 Henry J.M. Barnett Scholarship) and the American Academy of Neurology (2020 Michael S. Pessin Stroke Leadership Prize), in addition to other notable awards, including the 2019 International Stroke Conference Paul Dudley White International Scholar Award, and the 2014 European Stroke Conference Young Investigator Award.
Achieving our vision of a life free from stroke is a task that WSO cannot achieve alone. We are committed to building our partnerships at the global, regional and national level to scale up and deliver improvements in prevention, treatment and support to reduce the burden of stroke.
With support from:
*All WSO educational programs are independently developed and delivered.